Meningitis

2 original drugs

Novel Drugs

Reformulations

Active Trials

Drug Targets

Meningitis has 2 FDA-approved novel treatments, led by Pfizer across 1 drug target. Explore market leaders, treatments by mechanism, the clinical pipeline, and drug targets below.

Meningitis Market Leaders

Companies with the most FDA-approved novel Meningitis drugs.

Phase 3 Readouts Pro

5 active Phase 3 trials with confidence-graded completion dates.

Full calendar →

Q4 2026

experimental vaccine

Sinovac Biotech Co., Ltd

Estimated · fresh NCT07505888

Q1 2027

experimental vaccine

Sinovac Biotech Co., Ltd

Estimated · fresh NCT07505836

Q2 2027

experimental vaccine

Sinovac Biotech Co., Ltd

Estimated · fresh NCT07505810

Unlock 2 more readouts with confidence-graded estimates

Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Meningitis Clinical Pipeline by Phase

95 industry-sponsored trials across 20 sponsors

Showing 12 of 12 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
GSK	rMenB+OMV NZ	—	ACTIVE NOT RECRUITING	2026-09-07	NCT06113198
CanSino Biologics Inc.	MCV4	—	ACTIVE NOT RECRUITING	2026-05-15	NCT05935176
CanSino Biologics Inc.	MCV4	—	ACTIVE NOT RECRUITING	2025-12	NCT06389513
GSK	rMenB+OMV NZ vaccine	—	COMPLETED	2022-05-27	NCT03493919
Walvax Biotechnology Co., Ltd.	Yuxi Walvax MPV ACYW® vaccine	—	COMPLETED	2021-07-30	NCT04450498
Sanofi	Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine	—	COMPLETED	2019-06-12	NCT02864927
Sanofi	Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate	—	COMPLETED	2016-03-16	NCT02591290
Sanofi	Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine	—	COMPLETED	2016-02	NCT02633787
Sanofi	Meningococcal polysaccharide diphtheria toxoid conjugate	—	COMPLETED	2014-11	NCT01659996
Sanofi	Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate	—	COMPLETED	2013-12	NCT01270503
Novartis	MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine	—	COMPLETED	2012-12	NCT01424644
Sanofi	Meningococcal (Groups A and C) Polysaccharide Vaccine	—	COMPLETED	2012-08	NCT01430611

Showing 47 of 47 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
CanSino Biologics Inc.	MCV4	—	ACTIVE NOT RECRUITING	2025-08-30	NCT06700148
CanSino Biologics Inc.	MCV4	—	ACTIVE NOT RECRUITING	2024-09-26	NCT06226714
CanSino Biologics Inc.	batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4)	—	ACTIVE NOT RECRUITING	2024-07-12	NCT06131554
Sinovac Biotech Co., Ltd	experimental vaccine	—	NOT YET RECRUITING	2026-11	NCT07505888
Sinovac Biotech Co., Ltd	experimental vaccine	—	NOT YET RECRUITING	2027-01	NCT07505836
Sinovac Biotech Co., Ltd	experimental vaccine	—	NOT YET RECRUITING	2027-04	NCT07505810
Sinovac Biotech Co., Ltd	experimental vaccine	—	NOT YET RECRUITING	2027-04	NCT07505823
GSK	rMenB+OMV NZ vaccine	—	COMPLETED	2025-12-08	NCT06995430
CanSino Biologics Inc.	MCV4	—	COMPLETED	2023-12-11	NCT06011200
GSK	MenACWY vaccine	—	COMPLETED	2023-05-03	NCT04707391
Serum Institute of India Pvt. Ltd.	NmCV-5	—	COMPLETED	2020-02-23	NCT03964012
Tanabe Pharma Corporation	DPT-IPV-Hib	—	COMPLETED	2019-09-18	NCT03891758
Sanofi	MenACYW conjugate vaccine	—	COMPLETED	2018-07-19	NCT03205371
Sanofi	Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine	—	COMPLETED	2017-10-26	NCT02955797
Sanofi	Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate	—	COMPLETED	2017-10-10	NCT03077438
Sanofi	Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine	—	COMPLETED	2017-02-28	NCT02842853
Sanofi	Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine	—	COMPLETED	2017-02-13	NCT02842866
Sanofi	Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine	—	COMPLETED	2016-12-19	NCT02752906
Sanofi	DTaP-IPV/Hib Combined vaccine	—	COMPLETED	2016-05-28	NCT02274285
Sanofi	Meningococcal Diphtheria Toxoid Vaccine	—	COMPLETED	2016-04-12	NCT01890759
Novartis Vaccines	Bexsero® vaccine (1 dose at study month zero)	—	COMPLETED	2015-09	NCT01894919
Beijing Minhai Biotechnology Co., Ltd	Group T	—	COMPLETED	2015-05	NCT02003313
Novartis	Meningococcal (group B) multicomponent recombinant adsorbed vaccine	—	COMPLETED	2015-04	NCT02305446
Pfizer	rLP2086 vaccine	—	COMPLETED	2014-09	NCT01352793
Beijing Minhai Biotechnology Co., Ltd	MCV-ACYW135 Vaccine Group	—	COMPLETED	2014-08	NCT02003495
Novartis	Meningococcal ACWY conjugate vaccine	—	COMPLETED	2014-04	NCT01547715
Novartis Vaccines	Recombinant meningococcal B + OMV NZ	—	COMPLETED	2014-03	NCT01478347
Novartis Vaccines	rMenB + OMV NZ vaccine	—	COMPLETED	2014-01	NCT01339923
Novartis Vaccines	1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine	—	COMPLETED	2013-09	NCT01717638
Novartis Vaccines	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine	—	COMPLETED	2013-04	NCT01148017
Sanofi	Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)	—	COMPLETED	2013-01	NCT01642589
Novartis Vaccines	MenACWY-CRM conjugate vaccine	—	COMPLETED	2012-11	NCT00856297
Sanofi	Meningococcal polysaccharide diphtheria toxoid conjugate	—	COMPLETED	2012-09	NCT01519713
Sanofi	Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®	—	COMPLETED	2012-07	NCT01359449
Novartis Vaccines	MenACWY-CRM	—	COMPLETED	2012-04	NCT01214837
Novartis	Typhoid Vi Polysaccharide Vaccine	—	COMPLETED	2012-04	NCT01466387
Novartis Vaccines	No Vaccine	—	COMPLETED	2012-01	NCT01148524
Novartis Vaccines	MenACWY-CRM	—	COMPLETED	2012-01	NCT01453348
Novartis	Meningococcal ACWY conjugate vaccine	—	COMPLETED	2012-01	NCT01410474
Novartis	Serogroup B meningococcal vaccine	—	COMPLETED	2011-12	NCT01423084
Novartis Vaccines	rMenB+OMV NZ with routine vaccinations	—	COMPLETED	2011-08	NCT00944034
Novartis	MenACWY-CRM197	—	COMPLETED	2011-03	NCT00806195
Novartis Vaccines	Novartis MenACWY-CRM	—	COMPLETED	2011-03	NCT01274897
Sanofi	Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)	—	COMPLETED	2011-02	NCT01086969
Novartis Vaccines	Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)	—	COMPLETED	2010-01	NCT00657709
Pfizer	Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)	—	COMPLETED	2009-08	NCT00617760
Novartis Vaccines	MenACWY-CRM197 (two doses)	—	COMPLETED	2009-07	NCT00667602

Showing 29 of 29 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
GSK	—	—	ACTIVE NOT RECRUITING	2027-03-10	NCT05087056
BioVersys AG	BV100 with 50 mg polymyxin B plus ceftazidime/avibactam	—	NOT YET RECRUITING	2028-03	NCT07431307
BioVersys AG	HRZE	—	NOT YET RECRUITING	2028-03-30	NCT07350174
Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd	Meningococcal ACYW135 Polysaccharide Conjugate Vaccine	—	COMPLETED	2019-11-21	NCT05229536
GSK	MenACWY liquid	—	COMPLETED	2019-07-26	NCT03433482
GSK	MenABCWY vaccine	—	COMPLETED	2018-12-19	NCT03587207
Serum Institute of India Pvt. Ltd.	Non-adjuvanted study formulation NmCV-5	—	COMPLETED	2018-08-31	NCT03295318
Astellas	Micafungin	—	COMPLETED	2018-04-10	NCT03421002
Sanofi	Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine	—	COMPLETED	2016-12-05	NCT02640404
Sanofi	Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine	—	COMPLETED	2015-10-02	NCT02199691
Sanofi	Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine	—	COMPLETED	2015-08-19	NCT03205358
JN-International Medical Corporation	Test Vaccine	—	COMPLETED	2014-05	NCT01897402
Pfizer	meningococcal B rLP2086 vaccine.	—	COMPLETED	2014-03	NCT00808028
Pfizer	rLP2086	—	COMPLETED	2014-02	NCT01768117
Sanofi	Meningococcal Polysaccharide (A, C, Y, and W 135) Tetanus Protein Conjugate Vaccine	—	COMPLETED	2013-01-17	NCT01732627
Novartis	MenC-CRM LIQ	—	COMPLETED	2012-11	NCT01434680
Pfizer	rLP2086	—	COMPLETED	2012-10-08	NCT01323270
Sanofi	Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®	—	COMPLETED	2012-06	NCT01442675
Sanofi	Quadrivalent Meningococcal Polysaccharide (A, C, Y, and W-135) Tetanus Protein Conjugate	—	COMPLETED	2012-02-13	NCT01049035
Novartis Vaccines	Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine	—	COMPLETED	2012-01	NCT01367158
Novartis Vaccines	Meningococcal Vaccine	—	COMPLETED	2011-07	NCT01210885
Sanofi	Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide	—	COMPLETED	2011-04	NCT01239043
Novartis Vaccines	Meningococcal B vaccine	—	COMPLETED	2010-11	NCT00937521
Novartis Vaccines	Novartis Meningococcal (MenACWY-CRM) vaccine	—	COMPLETED	2010-07	NCT01018732
Wyeth is now a wholly owned subsidiary of Pfizer	meningococcal B rLP2086 vaccine candidate	—	COMPLETED	2010-05	NCT00780806
Sanofi	Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate	—	COMPLETED	2009-05	NCT00700635
Sanofi	Meningococcal polysaccharide diphtheria toxoid conjugate	—	COMPLETED	2009-02	NCT00700713
MacroGenics	MGAWN1	—	TERMINATED	2011-02	NCT00927953
Pfizer	meningococcal B rLP2086 vaccine	—	TERMINATED	2009-06	NCT00798304

Showing 7 of 7 trials

Sponsor	Asset	MoA	Status	Primary Completion	NCT
CanSino Biologics Inc.	Adsorbed Acellular Pertussis (3-Component) Diphtheria-Tetanus-Pertussis-Haemophilus influenzae type b (Conjugate)-Meningococcal Group ACYW135 (Conjugate) Combined Vaccine (DTcP-Hib-MCV4)	—	RECRUITING	2029-02	NCT07203755
Sinovac Life Sciences Co., Ltd.	high-dose Group ACYW135X Meningococcal Conjugate Vaccine	—	NOT YET RECRUITING	2026-09-10	NCT07374510
JN-International Medical Corporation	meningococcal meningitis conjugate vaccine, quadrivalent	—	COMPLETED	2013-01	NCT01482052
Mundipharma Research Limited	Whole Brain Radio Therapy (WBRT) with sequential Depocyte	—	COMPLETED	2012-10	NCT00854867
Pfizer	rLP2086 vaccine or control	—	COMPLETED	2012-07	NCT00879814
Sanofi	Meningococcal Polysaccharide Tetanus Protein Conjugate	—	COMPLETED	2009-02	NCT00631995
Johnson & Johnson	Doripenem	—	TERMINATED	2012-05	NCT01366651

Novel Meningitis Drugs by Company (New molecular entities)

2 companies have an FDA-approved novel drug for Meningitis.

Pfizer 1 drug

MUNDIPHARMA 1 drug

Reformulations (3 drugs) Click to expand

Reformulations are FDA-approved versions of existing molecules in new dosage forms (e.g., oral solution vs tablet, extended-release vs immediate-release). They require a new NDA but use an already-proven active ingredient.

ARIKAYCE KIT

INSMED

T3 2018

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER